Venus Remedies has entered into a collaborative agreement with Israel-based generic drug maker Teva for selling an anti- cancer drug in the Canadian market. The drug is widely used for the treatment of malignant pleural mesothelioma and non-squamous non-small cell lung cancer.
Under this collaboration, the pharma major will be initially manufacturing the drug at its Venus Medicine Research Centre, its research unit, for assisting Teva in registrations. Thereafter, Venus Remedies will also use its manufacturing capabilities to support Teva in enhancing the business from this drug in the Canadian market.
Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.
